undamentalytics Newsletter

Niklason Laura E: insider trades

Chief executive at Humacyte, Inc. 5 open-market purchases and 15 sales not made under a pre-set plan, reported from August 27, 2021 to August 20, 2025.

Would copying Niklason Laura E’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 4 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on August 30, 2021 into $6,788 by November 2, 2026, −7.2% a year. The copy held shares only 12% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $11,986, +3.6% a year (the S&P 500 held throughout made $17,942, +12.0% a year). Beta against the index was 0.14. Twelve months after each report, the average purchase was −62.9% against the S&P 500 (median −67.9%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −69.4%. After their sales, the shares moved −80.0% against the index over 12 months on average (a negative figure means selling was the right call); 100% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$5.0k$10.0k$15.0k 202120222023202420252026 $17.9k$12.0k$6.8k
Copying Niklason Laura ES&P 500, same days investedS&P 500, held throughout $10,000 copying Niklason Laura E’s open-market purchases from August 30, 2021, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−7.2%
S&P 500, same days invested
+3.6% (held throughout +12.0%)
Time in shares
12%
Sharpe ratio (S&P 500)
−0.20 (0.52)
Biggest drop (S&P 500)
−68% (−25%)
Market sensitivity (beta)
0.14
Purchases copied
3

Trade by trade

Niklason Laura E: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 4 −23.7% −23.1% 0% 3 — — Not enough years
Purchases, 6 months after the report 4 −49.1% −51.4% 0% 3 — — Not enough years
Purchases, 12 months after the report 4 −62.9% −67.9% 0% 3 — — Not enough years
Purchases, 12 months after the trade 3 −69.4% −76.0% 0% 2 — — Not enough years
Sales, 3 months after the report 5 −29.9% −30.3% 100% 2 — — Not enough years
Sales, 12 months after the report 5 −80.0% −79.5% 100% 2 — — Not enough years
Sales, 12 months after the trade 5 −80.3% −79.3% 100% 2 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Humacyte, Inc. HUMA President, CEO and Director515August 27, 2021August 20, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 20, 2025August 18, 2025 HUMA Sale $3,733,191 not yetnot yetnot yet
November 20, 2024November 18, 2024 HUMA Sale $6,606,799 not yetnot yetnot yet
September 11, 2024September 9, 2024 HUMA Sale $2,364,521 −33.0%−91.6%−94.0%
August 29, 2024August 27, 2024 HUMA Sale $5,724,139 −32.5%−92.5%−93.0%
June 13, 2024June 11, 2024 HUMA Sale $4,519,404 −29.1%−78.0%−78.7%
June 4, 2024June 4, 2024 HUMA Purchase $14,999 −30.3%−79.5%−76.0%
June 4, 2024May 31, 2024 HUMA Sale $7,832,200 −30.3%−79.5%−79.3%
June 3, 2024June 3, 2024 HUMA Purchase $15,108 −19.3%−76.0%−78.2%
September 15, 2023September 14, 2023 HUMA Sale $5,560,000 not yetnot yetnot yet
August 21, 2023August 17, 2023 HUMA Sale $6,378,837 not yetnot yetnot yet
June 16, 2023June 15, 2023 HUMA Sale $1,560,000 not yetnot yetnot yet
June 15, 2023June 13, 2023 HUMA Sale $12,675,000 not yetnot yetnot yet
May 26, 2023May 25, 2023 HUMA Sale $7,218,750 not yetnot yetnot yet
December 19, 2022December 16, 2022 HUMA Sale $606,031 not yetnot yetnot yet
December 19, 2022December 15, 2022 HUMA Purchase $25,400 not yetnot yetnot yet
December 15, 2022December 13, 2022 HUMA Sale $1,945,509 not yetnot yetnot yet
September 19, 2022September 15, 2022 HUMA Sale $6,090,000 not yetnot yetnot yet
May 25, 2022May 23, 2022 HUMA Purchase $48,300 −18.4%−36.3%not yet
December 16, 2021December 14, 2021 HUMA Sale $2,730,386 −24.6%−58.6%−56.7%
August 27, 2021August 26, 2021 HUMA Purchase $15,225,000 −27.0%−59.8%−53.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Niklason Laura E traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.